Contineum Therapeutics (CTNM) risk factors, FY2024 10-K

Risks Related to Development, Clinical Testing, and Regulatory Approval

1. 01potential disruptions caused by public health emergencies (“PHEs”) such as COVID-19, including difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented, and other factors
2. 02the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering the clinical data insufficient for approval
3. 03it may take greater human and financial resources than we possess to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs, thereby limiting our ability to develop, diversify, and expand our product portfolio
4. 04We have and may continue to conduct future clinical trials outside of the United States. The FDA and other regulatory authorities or ethics committees may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business and financial condition
5. 05The timely completion of clinical trials in accordance with their protocols depends, among other things, on the ability to enroll a sufficient number of patients who remain in the trial until its conclusion
6. 06the risk that patients enrolled in clinical trials will drop out of the trials before completion; and
7. 07Interim and preliminary “top-line” data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and is subject to audit and verification procedures that could result in material changes in the final data
8. 08The administration of PIPE-791 and/or PIPE-307 may cause serious adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales
9. 09Any of these events could prevent us or J&J, as applicable, from achieving or maintaining market acceptance of PIPE-791 or PIPE-307, if approved, and could significantly harm our business, financial condition, results of operations and prospects
10. 10The market opportunities for the drug candidates we develop, if approved, may be smaller than we anticipate and, as a result, our commercial opportunities may be limited
11. 11We have never obtained marketing approval for any drug candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any drug candidate
12. 12Even if we obtain FDA approval for a drug candidate in the United States, we may never obtain approval for the drug candidate in any other jurisdiction or commercialize the drug candidate in the United States or in any other jurisdiction, which would limit our ability to realize its full market potential
13. 13Even if we obtain regulatory approval for any drug candidate, we will still face extensive and ongoing regulatory requirements and obligations, which may result in significant additional expense, and any drug candidates, if approved, may face future development and regulatory difficulties
14. 14injunctions, consent decrees, or the imposition of civil or criminal penalties
15. 15Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop
16. 16The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to change, including due to judicial challenges

Risks Related to our Financial Position and Need for Additional Capital

1. 17acquire or in-license other drug candidates or technologies
2. 18We have a limited operating history and the drug candidates we have developed are in the early stages of clinical development, which may make it difficult to evaluate the prospects for our future viability
3. 19We will require significant additional capital to complete the development and commercialization of PIPE-791 and the other drug candidates we select for development
4. 20the initiation, progress, and timing of our commercialization of any drug candidate for which we obtain regulatory approval

Risks Related to our Existing Collaboration Agreement and any Collaboration Agreements we may enter into in the Future

1. 21If the J&J License Agreement does not result in the successful development of PIPE-307, our business, financial condition and results of operations will be harmed
2. 22J&J may terminate the collaboration for convenience and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of PIPE-307
3. 23We may not recognize the financial and other benefits of any additional collaborations or strategic alliances that we may enter into in the future for the development and commercialization of our drug candidates
4. 24industry and market conditions generally

Risks Related to our Intellectual Property

1. 25Patent terms may be inadequate to protect our competitive position on our drug candidates for an adequate amount of time
2. 26If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for any drug candidates we may develop, our business may be materially harmed
3. 27Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
4. 28If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed
5. 29Although we are not currently involved in any litigation, we may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful
6. 30Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
7. 31Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities
8. 32Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
9. 33We may not be able to protect our intellectual property and proprietary rights throughout the world
10. 34We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
11. 35If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
12. 36If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
13. 37Intellectual property rights do not necessarily address all potential threats

Risks Related to our Dependence on Third Parties

1. 38in the event of approval to market and commercialize our drug candidates, an inability to meet commercial demands for our product or any other future drug candidates
2. 39form relationships with other entities, some of which may be our competitors
3. 40We intend to rely on CROs, and other third parties to conduct our preclinical studies. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business
4. 41Our third-party manufacturers may be unable to successfully scale-up manufacturing of our drug candidates in sufficient quality and quantity, which could delay or prevent us from developing our drug candidates and commercializing approved products, if any
5. 42Manufacturing of the API for PIPE-791 takes place in China, through a sole third-party manufacturer. A significant disruption in the operation of this manufacturer could materially adversely affect our business, financial condition and results of operations

Risks Related to Healthcare Laws and Other Legal Compliance Matters

1. 43Recent and future changes in healthcare legislation and regulations may increase the difficulty and cost to obtain marketing approval for a drug candidate, increase the costs to commercialize an approved product, and adversely affect the price set for such product
2. 44The ACA and its implementation continue to evolve as a result of legislative, administrative, and judicial developments. Further changes remain possible, which may potentially negatively affect pricing, coverage, or reimbursement for PIPE-791 and/or PIPE-307
3. 45Our business operations and current and future relationships with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, customers, and others will be subject to applicable healthcare regulatory laws, which could expose us to penalties
4. 46Any clinical trial programs, marketing, or research collaborations in the European Economic Area will subject us to the GDPR
5. 47We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities

Risks Related to our Employees, Managing our Growth and our Operations

1. 48Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel
2. 49We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
3. 50Our business and operations could be materially and adversely affected in the event of system failures
4. 51Our proprietary or confidential information may be lost, or we may suffer security breaches

Risks Related to Commercialization

1. 52We face significant competition from biotechnology, pharmaceutical, and medical device companies, and our operating results will suffer if we fail to compete effectively and in a timely manner
2. 53PIPE-791 for Progressive MS
3. 54PIPE-791 for Chronic Pain
4. 55Even if PIPE-791 or PIPE-307 receives marketing approval in an indication, it may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success
5. 56We have no sales, marketing or distribution capabilities or experience. If we are unable to establish sales and marketing capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing PIPE-791, even if approved
6. 57The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for an approved products could limit the ability to market the product and decrease the revenues we ultimately receive
7. 58A variety of risks associated with operating internationally could materially adversely affect our business
8. 59certain expenses, including, among others, expenses for travel, translation, and insurance; and

Risks Related to Ownership and our Common Stock

1. 60The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders
2. 61general economic, industry and market conditions
3. 62We have a limited trading history and there is no assurance that a robust market in our common stock will develop or be sustained
4. 63Sales of a substantial number of shares of our common stock in the public market could cause the price of our common stock to fall
5. 64Our directors, executive officers and holders of greater than 5% of our common stock own a significant percentage of our common stock and, if they choose to act together, will be able to exert significant influence over matters subject to stockholder approval
6. 65The dual series structure of our Class A and Class B common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions
7. 66We are an “emerging growth company,” and a “smaller reporting company” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies or smaller reporting companies will make our common stock less attractive to investors
8. 67not being required to disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer’s compensation to median employee compensation
9. 68We do not intend to pay cash dividends for the foreseeable future. Consequently, you must rely on sales of our common stock after price appreciation, which may never occur, as the only way to realize any future gains on your investment
10. 69Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock
11. 70If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
12. 71We could be subject to securities class action litigation
13. 72Requirements associated with being a public company will increase our costs significantly, as well as divert significant company resources and management attention
14. 73Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
15. 74Changes in tax laws and the implementation of tax laws could adversely affect us